I and many others on this forum have said again and again, Edwards should be seriously, seriously worried about the heat and competitive pressure AVR and their DurAVR will bring when it comes to market (Medtronic less so as they are heavily diversified, Edwards is not, around 85% of their revenues and I think an even higher %of their NPAT comes from TAVR.) It could spell the beginning of the end for Edwards, a US $60 Billion company.
The facts are on our side, the world's leading surgeons from US, EU and Australia, are on our side, and it sounds like we're gaining more and more attention at every new TAVR conference we present at.
It may even come to a point, where the evidence is so overwhelming and irrefutable (5-10 years down the track) where any Interventional Cardiologist who's not using the DurAVR is seen as a kind of pariah and outlier in his/her field!
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)